Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75

Author: Benzinga Newsdesk | October 22, 2025 06:34am

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $59 to $75.

Posted In: KYMR